14, producer's product information). In view of the potential toxicity and the producer's advice not to use the drug with chemotherapy regimens not containing anthracycline, we looked for an alternative antioxidant regimen as a potential cardioprotector in patients subjected to combined chemo-and radiotherapy. Vitamins E, C and N-acetylcysteine were chosen because of a potentially synergistic action of the combination,12,13) good patient acceptability as "natural substances" , absence of side effects with the chosen dosage and oral route of administration. In addition they are readily available and inexpensive. Due to the small patient numbers and the inhomogenous clinical characteristics of the patients, both groups not being age, sex and therapy-matched, the statistical significance is only formal and allows for both alpha or beta type bias. This fact is amply acknowledged in the analysis of the study. However, even if patients received different therapeutic regimens (randomization occured before allocation to treatment, thus these errors are truly "random"), the obvious fall in individual systolic ventricular performance in the placebo subgroup shows the need for cardioprotective therapy.
Three patients receiving antioxidants and 4 patients receiving placebo showed a rise in left ventricular ejection fraction after treatment completion (Figures 1 and 2) . Except for 2 patients in the antioxidant group, the rise was less than 5% and can thus be fully accounted for by the inherent divergence described when performing repeated assessment of ventricular function using radionuclide ventriculography in healthy individuals.11) There was no noticeable change in the clinical or laboratory parameters (fever etc.) of the 2 patients with a rise of 6% and 7% in ejection fraction, so that a different cardiac loading status must be postulated, enhancing the methodological variability, to explain the rise in ejection fraction. If the results are recalculated so that all ejection fractions showing an increase are assumed to have remained stationary, then the mean ejection fraction of the group receiving antioxidants will decrease significantly (p=0.01). The decrease in ejection fraction of the placebo group will increase in statistical significance to p=0.004. These changes may be formally significant, yet they lack clinical meaning, as no individual patient in the antioxidant group showed a clinically significant decrease in ejection fraction of >5% (Figure 1) . It is for this reason that a cut off value of 10% reduction in ejection fraction was chosen in our study to be clinically significant, thus ensuring that only very obvious worsening of systolic function was accredited to cardiotoxicity .
Because a span of 1 1/2 years was allowed for the study (financial constraints, availability of study participants, etc.), it could not be extended until a larger number of patients could be included. The study has focused on reduction of short term deterioration of left ventricular ejection fraction. The more important question of whether antioxidant therapy can reduce long term cardiotoxic effects was not addressed. Because of the individually tailored chemotherapy regimens, dosage comparisons yield only limited information as to their potential cardiotoxicity. Although radiotherapy doses to the heart and left ventricle did not differ significantly between the two groups, the results may still be biased in favor of antioxidant therapy because of the large SD and small number of patients. Additionally, 2 patients randomized to the placebo group suffered from esophageal malignancy, and therefore received higher radiation doses than average.
CONCLUSIONS
The antioxidant combination featuring vitamin E and C as well as Nacetylcysteine may provide efficient cardioprotection in patients receiving high dose chemo-or radiotherapy. Although the small number of patients precludes more than cautious interpretation of any statitistical significance, the encouraging results of this double blind study warrant confirmation by larger ones.
